News Asterias Biotherapeutics Inc

Stocks

AST

US04624N1072

Biotechnology & Medical Research

Delayed NYSE			5-day change	1st Jan Change
- ^USD	-.--%		+3.85%	+52.42%

All News

Mentions Relevance

19-01-24	Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury	GL
18-11-09	Asterias Biotherapeutics Reports Third Quarter Results	GL
18-11-08	Asterias Biotherapeutics : BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company	BU
18-11-08	Asterias Biotherapeutics : BioTime Reports Third Quarter 2018 Financial Results and Provides Business Update	BU
18-10-01	Asterias Biotherapeutics Announces Facilities and IP License Option Agreements	GL
18-09-20	FDA Accepts Asterias Biotherapeutics’ Request to Meet and Discuss Next Phase of Development for OPC1 Spinal Cord Injury Clinical Program	GL
18-09-04	Asterias Biotherapeutics Announces Positive Outcome from Second Safety Review Committee Meeting and Open Enrollment for VAC2 Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)	GL
18-08-29	Asterias Biotherapeutics’ CEO Michael Mulroy to Participate on Regenerative Medicine Therapies Panel at the B. Riley FBR Healthcare Conference	GL
18-08-09	Asterias Biotherapeutics Reports Second Quarter Financial Results and Recent Development Progress	GL
18-07-31	Asterias Provides 12 Month Cohort 3 and 4 Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury	GL
18-07-26	Asterias Biotherapeutics to Report Second Quarter 2018 Results on August 9, 2018	GL
18-07-17	Asterias Provides Six Month Data Readout for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury	GL
18-07-12	Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California for Stroke IP; Second Pre-Clinical Collaboration Initiated to Test the Efficacy of AST-OPC1 for the Treatment of Stroke	GL
18-06-12	Asterias Biotherapeutics Announces First Patient Dosed in First-in-Human Clinical Study of Immunotherapy AST-VAC2 in Non-Small Cell Lung Cancer	GL
18-06-05	Asterias Biotherapeutics Announces Independent Data Monitoring Committee Completes Last Intermediate Review of AST-OPC1 Clinical Trial in Acute Spinal Cord Injury	GL
18-05-16	Asterias Biotherapeutics to Discuss Cancer Immunotherapy Product AST-VAC2 at the World Advanced Therapies and Regenerative Medicine Congress	GL
18-05-03	Asterias Biotherapeutics to Report First Quarter 2018 Results on May 9, 2018	GL
18-05-02	Asterias Biotherapeutics to Present Safety and Efficacy Data from AST-OPC1 SCiStar Study at the American Spinal Injury Association (ASIA) 2018 Annual Meeting	GL
18-04-27	Asterias Biotherapeutics to Present AST-OPC1 Program Update at the Upcoming American Society for Neural Therapy and Repair Conference	GL
18-04-25	Asterias Announces Clinical Grade Lot Released to Support Dosing of First Subjects in First Clinical Study of AST-VAC2	GL
18-03-15	Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Developments	GL
18-03-09	Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2017 Results on March 15, 2018	GL
18-02-28	Asterias Provides Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury	GL
18-02-15	Asterias Expands Global IP Portfolio with New Patents, Including Key Additional Patent Protection for its Cancer Immunotherapy Program	GL
18-01-04	Asterias Biotherapeutics Reports Milestone Targets for 2018	GL